Keyphrases
Demographic Data
25%
Dundee
25%
Hypophysitis
100%
Immune Checkpoint Inhibitor Toxicity
100%
Immune Checkpoint Inhibitors
100%
Immune-related Adverse Events
100%
Ipilimumab
50%
Melanoma
100%
Melanoma Patients
25%
Metastatic Melanoma
50%
Nivolumab
25%
Overall Survival
25%
Patient Demographics
25%
Pembrolizumab
25%
Progression-free Survival
25%
Scottish
100%
Medicine and Dentistry
Adverse Event
100%
Hypophysitis
100%
Immune Checkpoint Inhibitor
100%
Immunity
100%
Ipilimumab
50%
Melanoma
100%
Metastatic Melanoma
50%
Nivolumab
25%
Overall Survival
25%
Pembrolizumab
25%
Progression Free Survival
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Hypophysitis
100%
Immune Checkpoint Inhibitor
100%
Ipilimumab
50%
Melanoma
100%
Metastatic Melanoma
50%
Nivolumab
25%
Overall Survival
25%
Pembrolizumab
25%
Progression Free Survival
25%